Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of (177)Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

(177)Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen (PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported favorable activity with low toxicity in a prospective phase II trial involving 30 men with metastatic castration-resista...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Nucl Med
Hlavní autoři: Violet, John, Sandhu, Shahneen, Iravani, Amir, Ferdinandus, Justin, Thang, Sue-Ping, Kong, Grace, Kumar, Aravind Ravi, Akhurst, Tim, Pattison, David, Beaulieu, Alexis, Mooi, Jennifer, Tran, Ben, Guo, Christina, Kalff, Victor, Murphy, Declan G, Jackson, Price, Eu, Peter, Scalzo, Mark, Williams, Scott, Hicks, Rodney J., Hofman, Michael S.
Médium: Artigo
Jazyk:Inglês
Vydáno: Society of Nuclear Medicine 2020
Témata:
Theranostics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7262220/
https://ncbi.nlm.nih.gov/pubmed/31732676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.119.236414
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky